Flash Player 9.0.0 is required for the Video Gallery. Get Adobe Flash Player.
Colleague's E-mail is Invalid
Your message has been successfully sent to your colleague.
Video Author: Mithra Pharmaceuticals (sponsor) Published on: 08.05.2020 Associated with: Menopause. 27(8):848-857, August 2020
This video summarizes the results of a study to select the minimum effective dose of estetrol (E4) for the treatment of postmenopausal women with vasomotor symptoms (VMS, hot flushes). The reduction in frequency and severity of VMS was most pronounced for 15 mg E4, and was significant at week 4 and 12. E4 was well tolerated and there were no unexpected adverse events. It was concluded that oral E4 15 mg is the minimum effective daily oral dose for treatment of VMS.
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. For information on cookies and how you can disable them visit our Privacy and Cookie Policy.